Caplin Point Laboratories delivered robust financial results for the quarter ended March 2026, with consolidated net profit rising 19.32% to ₹170.11 crore compared to ₹142.57 crore in the corresponding quarter of the previous year. According to latest reports, the pharmaceutical company's sales grew 19.45% to ₹600.16 crore in Q4 FY26, up from ₹502.45 crore in Q4 FY25. The company maintained healthy operational margins with operating profit margin (OPM) at 34.03% for the quarter. Earnings per share (EPS) for the quarter stood at ₹22.31, representing a 19.37% increase from ₹18.69 in Q4 FY25.
The company demonstrated strong sequential performance with total income of ₹628.52 crore in Q4 FY26, marking a 9.03% increase from ₹576.45 crore in Q3 FY26. As per the latest financial results, net profit for Q4 FY26 was ₹170.11 crore, showing a 3.80% growth from ₹163.88 crore in the previous quarter. EPS for the quarter reached ₹22.31, compared to ₹21.51 in Q3 FY26, reflecting consistent operational efficiency and market positioning in the pharmaceutical sector.
For the complete financial year ended March 2026, Caplin Point Laboratories demonstrated consistent growth momentum. Total income for FY26 reached ₹2,302.73 crore, representing a 13.22% increase from ₹2,033.90 crore in FY25. The company's annual net profit increased 19.57% to ₹641.24 crore compared to ₹536.31 crore in the previous financial year. Annual EPS stood at ₹84.11, showing a 19.73% increase from ₹70.25 in FY25, demonstrating the company's strong earnings growth trajectory across all financial metrics.
The company's profit before depreciation and tax (PBDT) for Q4 FY26 was ₹232.24 crore, marking an 18% increase from ₹193.71 crore in Q4 FY25. According to the latest financial data, profit before tax (PBT) for the quarter reached ₹213.44 crore, representing a 21% growth from ₹176.67 crore in the corresponding quarter of the previous year. The strong performance across all profitability metrics reflects the company's operational efficiency and market positioning in the pharmaceutical sector.
Shares of Caplin Point Laboratories Limited were trading at ₹2,023.05 on BSE as of the latest trading session, compared to the previous close of ₹1,843.00. The stock demonstrated strong market performance with total shares traded of 162,770 in over 10,555 trades during the session. The stock hit an intraday high of ₹2,057.10 and intraday low of ₹1,806.00, with net turnover of ₹325.16 crore during the trading day, indicating positive investor sentiment following the strong quarterly results.
